Segurança da vacinação contra a COVID-19 em doentes referenciados dos cuidados de saúde primários por alergia ao veneno de himenópteros
COVID-19 vaccination safety in patients with hymenoptera venom allergy referred by primary health care
Ricardo José Brás; Joana Cosme; Rita Brás; Elisa Pedro; Amélia Spínola Santos
Resumo
Introdução: As reações de hipersensibilidade após vacinação contra a COVID-19 têm vindo a ser descritas, embora a anafilaxia seja rara. A hipersensibilidade ao veneno de himenópteros constitui a terceira causa mais frequente de anafilaxia em Portugal, embora não pareça aumentar o risco de anafilaxia à vacinação contra a COVID-19. Objetivos: Avaliar a segurança da vacinação contra a COVID-19 em doentes com história de alergia ao veneno de himenópteros referenciados dos Cuidados de Saúde Primários (CSP). Métodos: Estudo observacional retrospectivo com inclusão dos doentes com alergia ao veneno de himenópteros referenciados pelos CSP ao serviço de Imunoalergologia, para estratificação do risco de reações de hipersensibilidade à vacina contra o SARS-CoV-2, entre janeiro e dezembro de 2021. Resultados: No total, incluíram-se 18 doentes, 72% do sexo feminino, média de idades de 61±18 [21-89] anos. Na caracterização do tipo da reação ao veneno de himenópteros, as reações locais exuberantes corresponderam a 33% de todas as reações referidas. Quanto a sintomas sistêmicos de anafilaxia, foram referidos sintomas mucocutâneos (33%), respiratórios (28%), cardiovasculares (33%) e gastrointestinais (11%). A abelha foi o inseto mais frequentemente implicado (61%). Relativamente aos valores de triptase basal, 3 doentes apresentaram níveis acima do cut-off estabelecido de 11,4 ng/mL, tendo indicação formal para iniciar esquema de vacinação em meio hospitalar. Durante o processo vacinal registrou-se um total de 46 administrações em 18 doentes, todas sem intercorrências. Apenas 5 doentes foram vacinados em meio hospitalar, tendo sido os restantes encaminhados para os CSP. Os doentes com mastocitose confirmada ou suspeita foram submetidos à pré-medicação com anti-histamínico anti-H1 e antiH2, bem como montelucaste, na véspera e no dia da vacinação. Conclusões: A vacinação contra a COVID-19 é segura em doentes com reação de hipersensibilidade ao veneno de himenópteros. O protocolo utilizado mostrou ser eficaz na segregação de doentes entre CSP e cuidados secundários/terciários.
Palavras-chave
Abstract
Introduction: Despite numerous reports of hypersensitivity reactions to COVID-19 vaccination, anaphylaxis is rare. Although hypersensitivity reactions to hymenoptera venom are the third most common cause of anaphylaxis in Portugal, they don’t appear to enhance the risk of anaphylactic reaction to COVID-19 vaccination. Objectives: To assess the safety of COVID-19 vaccination in patients with a history of hymenoptera venom allergy. Methods: This retrospective observational study included patients with hymenoptera venom allergy referred by primary health care to the Immunoallergology Outpatient Clinic of a tertiary hospital between January and December 2021 to stratify the risk of hypersensitivity reactions to the SARSCoV-2 vaccine. Results: A total of 18 patients were included: 72% women; mean age 61 (SD, 18 [range 21-89]) years. One-third of all reported reactions to hymenoptera venom were large and local. Topical systemic symptoms of anaphylaxis were mucocutaneous (33%), respiratory (28%), cardiovascular (33%) and gastrointestinal (11%). The honeybee was the most frequently involved hymenoptera species (61%). The basal tryptase levels of 3 patients were above the established cut-off (11.4 ng/mL) and they were formally indicated for vaccination in a hospital setting. Concerning the vaccination process, 46 doses were administered to the 18 patients and no reactions were recorded. Only 5 patients were vaccinated in a hospital environment; the rest were referred to primary health care centers. Patients with confirmed or suspected mastocytosis were premedicated with anti-H1 and anti-H2 antihistamines, as well as montelukast, the day before and on the day of vaccination. Conclusions: COVID-19 vaccination is safe for patients with hypersensitivity to hymenoptera venom. The risk assessment protocol effectively designated patients to primary or secondary/tertiary health care.
Keywords
References
1. Dreskin SC, Halsey NA, Kelso JM, Wood RA, Hummell DS, Edwards KM, et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J. 2016;9(1):32.
2. Edwards AKM, Orenstein WA. COVID-19: Vaccines. Uptodate [Internet]. 2022. Disponível em: https://www.uptodate.com/contents/covid-19-vaccines?search=sars-cov-2vaccination&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#references. Acessado em: 21/10/2022.
3. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21(2):e26-e35.
4. Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, Türeci Ö, Pather S, et al. Clinical development and approval of COVID-19 vaccines. Expert Rev Vaccines. 2022;21(5):609-19.
5. Infarmed. Relatório de Farmacovigilância - Monitorização da segurança das vacinas contra a Covid -19 em Portugal [Internet]. Infarmed; 2022. Disponível em: https://www.infarmed.pt/documents/15786/4268692/Relatório+de+Farmacovigilância.+Monitorização
+da+segurança+das+vacinas+contra+a+COVID+19+em+Portugal+atualizado+31+janeiro+2022/709e77f5-ab06 092d-338b-44c99586f796
6. Rama TA, Miranda J, Silva D, Amaral L, Castro E, Coimbra A, et al. COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication. Vaccines. 2022;10(5):1-9.
7. Carvalho JC, Cunha F, Coutinho IA, Loureiro C, Faria E, Bom AT. Hypersensitivity reactions to vaccines: Current evidence and standards for SARS-CoV-2 vaccines. Acta Med Port. 2021;34(13).
8. Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract. 2021;9(10):3546-67.
9. Maltezou HC, Anastassopoulou C, Hatziantoniou S, Poland GA, Tsakris A. Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines. Vaccine. 2022;40(2):183-6.
10. Portugal, DGS - Direção-Geral da Saúde. Campanha de Vacinação contra a COVID-19 - Vacina SPIKEVAX® [Internet]. Norma da DGS n° 001/2021 de 14/01/2021. Portugal: DGS; 2021. p. 1-25. Disponível em: https://covid19.min-saude.pt/wp-content/uploads/2022/02/Norma_001_2021_act_03112021_pdf-1091kb.pdf.
11. Portugal, DGS - Direção-Geral da Saúde. Campanha de Vacinação contra a COVID-19 - Vacina VAXZEVRIA [Internet]. Norma da DGS n° 003/2021 de 08/02/2021. Portugal: DGS; 2021. p. 1-22. Disponível em: https://covid19.min-saude.pt/wp-content/uploads/2022/02/Norma_003_2021_act_17062021_pdf-1114kb.pdf.
12. Portugal, DGS - Direção-Geral da Saúde. Campanha de Vacinação contra a COVID-19 Vaccine Janssen® [Internet]. Norma n° 004/2021 de 30/04/2021 atualizada a 08/06/2021. Portugal: DGS; 2021. p. 1-24. Disponível em: https://www.dgs.pt/normas-orientacoes-einformacoes/normas-e-circulares-normativas/norma-n-0042021-de-30042021-pdf.aspx.
13. Portugal, DGS - Direção-Geral da Saúde. Campanha de Vacinação contra a COVID-19 - Vacina COMIRNATY® [Internet]. Norma da DGS n° 021/2020 de 23/12/2020. Portugal; 2021. Disponível em: https://www.sip-spp.pt/media/ilmffvrz/vacina-comirnaty-norma-021_2020-20_08_2021.pdf.
14. Gaspar A, Santos N, Faria E, Câmara R, Rodrigues-Alves R, Carrapatoso I, et al. Anaphylaxis: A Decade of a Nationwide Allergy Society Registry. J Investig Allergol Clin Immunol. 2022;32(1):23‑32.
15. Gaspar Â, Santos N, Faria E, Pereira AM, Gomes E, Câmara R, et al. Anaphylaxis in children and adolescents: The Portuguese Anaphylaxis Registry. Pediatr Allergy Immunol. 2021;32(6):1278‑86.
16. Ruëff F, Placzek M, Przybilla B. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol. 2006 Aug;6(4):284-8.
17. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008 Feb;63(2):226-32.
18. Rama TA, Moreira A, Castells M. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis. J Allergy Clin Immunol. 2021 Mar;147(3):877-8
19. Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M, et al.; EAACI Food Allergy and Anaphylaxis Guidelines Group. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014 Aug;69(8):1026‑45.
20. Mueller UR. Insect sting allergy: clinical picture, diagnosis and treatment. Gustav Fischer; 1990. p. 33-65.
21. Sociedade Portuguesa de Alergologia e Imunologia Clínica - Grupo de Interesse de Alergia a Fármacos. Protocolo de atuação na vacinação contra SARS-CoV-2 nos Serviços de Imunoalergologia Portugueses. Portugal: SPAIC; 2022.
22. Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al.; WAO Anaphylaxis Committee. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021 Feb;14(2):100517.
23. Klimek L, Jutel M, Akdis CA, Bousquet J, Akdis M, Torres MJ, et al. ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper. Allergy. 2021;76(6):1624-8.
24. Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy Eur J Allergy Clin Immunol. 2021;76(6):1629-39.
25. Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Mayorga C, et al. Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper. Allergy Eur J Allergy Clin Immunol. 2022;77(8):2292-312.
26. Bonadonna P, Brockow K, Niedoszytko M, Elberink HO, Akin C, Nedoszytko B, et al. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). J Allergy Clin Immunol Pract. 2021;9(6):2139-44.
27. Ieven T, Vandebotermet M, Nuyttens L, Devolder D, Vandenberghe P, Bullens D, et al. COVID-19 Vaccination Safety and Tolerability in Patients Allegedly at High Risk for Immediate Hypersensitivity Reactions. Vaccines (Basel). 2022;10(2):286.
28. Nittner-Marszalska M, Rosiek-Biegus M, Kopec A, Pawłowicz R, Kosinska M, Łata A, et al. Pfizer-biontech COVID-19 vaccine tolerance in allergic versus non-allergic individuals. Vaccines. 2021;9(6):553.
29. Ruano-Zaragoza M, Carpio-Escalona LV, Diaz-Beya M, Piris- Villaespesa M, Castaño-Diez S, Muñoz-Cano R, et al. Safety of COVID-19 vaccination in patients with clonal mast cell disorders. J Allergy Clin Immunol Pract. 2022;10(5):1374-1376.e3.
30. Klimek L, Bergmann KC, Brehler R, Pfützner W, Zuberbier T, Hartmann K, et al. Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI. Allergo J Int. 2021;30(3):79-95.
31. Caminati M, Guarnieri G, Senna G. Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine? Vaccines (Basel). 2021;9(1):38.
32. Lazarinis N, Bossios A, Gülen T. COVID-19 vaccination in the setting of mastocytosis-Pfizer-BioNTech mRNA vaccine is safe and well tolerated. J Allergy Clin Immunol Pract. 2022 May;10(5):1377-9.
33. Rama T, Moreira A, Delgado L. Abordagem diagnóstica e terapêutica das mastocitoses - Uma proposta de orientação clínica. Rev Port Imunoalergologia. 2020;28(1):31-49.
34. Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey LH, et al.; European Academy of Allergy and Clinical Immunology, Food Allergy, Anaphylaxis Guidelines Group. EAACI guidelines: Anaphylaxis (2021 update). Allergy. 2022;77(2):357-77.
Submitted date:
04/18/2023
Accepted date:
06/01/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email